PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
4.46M / 3.59M (Avg.)
-1.65 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1839247.40%
10Y CAGR of 1839247.40% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
No Data
No Data available this quarter, please select a different quarter.
2405.31%
3Y CAGR of 2405.31% while CRN.AX is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
185.47%
OCF/share CAGR of 185.47% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
144.47%
OCF/share CAGR of 144.47% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
219.67%
3Y OCF/share CAGR of 219.67% while CRN.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
75.04%
10Y net income/share CAGR of 75.04% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
95.60%
Net income/share CAGR of 95.60% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
-130.58%
Negative 3Y CAGR while CRN.AX is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.95%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-78.61%
Negative 5Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
240.87%
Equity/share CAGR of 240.87% while CRN.AX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.